Urinary Track Infection Prevention After Urogynecological Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

July 1, 2021

Study Completion Date

July 1, 2021

Conditions
Urinary Tract InfectionsUrinary Retention PostoperativePelvic Organ Prolapse
Interventions
DRUG

Methenamine Hippurate 1 g tablet

Methenamine Hippurate (study drug) is an FDA approved medication in the prevention of UTI. Methenamine Hippurate 1g contains Hippuric acid salt of Methenamine (hexamethylene tetramine), Magnesium Stearate, Povidone, Saccharin Sodium, FD\&C Yellow No. 5 (tartrazine) (www.iodine.com/drug/hiprex/fda-package-insert).

DRUG

Placebo tablet

Placebo is a tablet that will be provided to you that looks like the study drug but does not contain any medication. These pills are comprised of gelatin and minimal amounts of lactose powder. The pills are designed to have no effect on the patient.

Trial Locations (1)

45220

Cincinnati Urogynecology Associates, Cincinnati

All Listed Sponsors
lead

TriHealth Inc.

OTHER

NCT03818321 - Urinary Track Infection Prevention After Urogynecological Surgery | Biotech Hunter | Biotech Hunter